Phase II angiogenesis stimulators

Expert Opinion on Investigational Drugs

Volumn 22, Issue 9, 2013, Pages 1157-1166

  Ribatti, Domenico ^a   Baiguera, Silvia ^b  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Angiogenesis; Gene transfer; Therapeutic angiogenesis; VEGF

Indexed keywords

ADENOVIRUS VECTOR; ADRENOMEDULLIN; ANGIOGENIC FACTOR; ANGIOPOIETIN; ANGIOTENSIN II; BECAPLERMIN; COLONY STIMULATING FACTOR 1; ENDOTHELIN; ERYTHROPOIETIN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; PLACEBO; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR; VASCULOTROPIN; VASCULOTROPIN 121; VASCULOTROPIN C;

ACUTE HEART INFARCTION; ANGIOGENESIS; ANGIOGENIC GENE THERAPY; ANTIANGIOGENIC GENE THERAPY; ANTIANGIOGENIC THERAPY; ARTERIOSCLEROSIS; BLOOD PRESSURE; BLOOD VESSEL PERMEABILITY; CAUSE OF DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; EXPECTATION; FIBRINOLYTIC THERAPY; GENE TRANSFER; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HUMAN; INTERMITTENT CLAUDICATION; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; PLASMID; PROTEIN DEGRADATION; REVASCULARIZATION; REVIEW; SHEAR STRESS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEM CELL; THORACOTOMY; TISSUE OXYGENATION; TISSUE REPAIR; WOUND HEALING;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; MYOCARDIAL ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC; OXYGEN; TREATMENT OUTCOME;

EID: 84882277092     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.813933     Document Type: Review

References (122)

1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57
2. Burbridge MF, Coge F, Galizzi JP, et al. The role of the matrix metalloproteinases during in vitro vessel formation. Angiogenesis 2002;5:215-26
3. Koolwijk P, Sidenius N, Peters E, et al. Proteolysis of the urokinase-type plasminogen activator receptor by metalloproteinase-12: implication for angiogenesis in fibrin matrices. Blood 2001;97:3123-31
4. Cornelius LA, Nehring LC, Harding E, et al. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 1998;161:6845-52
5. Autiero M, De Smet F, Claes F, Carmeliet P. Role of neural guidance signals in blood vessel navigation. Cardiovasc Res 2005;65:629-38
6. Li WW, Talcott KE, Zhai AW, et al. The role of therapeutic angiogenesis in tissue repair and regeneration. Adv Skin Wound Care 2005;18:491-500
7. Fischer C, Schneider M, Carmeliet P. Principles and therapeutic implications of angiogenesis, vasculogenesis and angiogenesis. Handbook of experimental pharmacology. Volume 176/II Springer; Heidelberg: 2006. p. 157-212
8. Davis GE, Stratman AN, Sacharidou A, Koh W. Molecular basis for endothelial lumen formation and tubulogenesis during vasculogenesis and angiogenic sprouting. Int Rev Cell Mol Biol 2011;288:101-65
9. Stratman AN, Davis GE. Endothelial cell pericyte interactions stimulate basement membrane matrix assembly: influence on vascular tube remodeling, maturation, and stabilization. Microsc Microanal 2012;18:68-80
10. Feng C, Han A, Ye C, et al. The HMG-CoA reductase pathway, statins and angioprevention. Semin Ophthalmol 2006;21:29-35
11. Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signaling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 2001;22:201-7
12. Ribatti D. The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: a historical review. Br J Haematol 2005;128:303-9
13. Suhardja A, Hoffman H. Role of growth factors and their receptors in proliferation of microvascular endothelial cells. Microsc Res Tech 2003;60:70-5
14. Turner HE, Harris AL, Melmed S, Wass JAM. Angiogenesis in endocrine tumors. Endocr Rev 2003;24:600-32
15. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611
16. Hoeben A, Landuyt B, Highley MS, et al. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004;56:549-80
17. Simons M. Integrative signaling in angiogenesis. Mol Cell Biochem 2004;264:99-102
18. Tait CR, Jones PF. Angiopoietins in tumours: the angiogenic switch. J Pathol 2004;204:1-10
19. Presta M, Dell'Era P, Mitola S, et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005;16:159-78
20. D'Andrea LD, Del Gatto A, Pedone C, Benedetti E. Peptide-based molecules in angiogenesis. Chem Biol Drug Des 2006;67:115-26
21. Folkman J. Angiogenesis. Annu Rev Med 2006;57:1-18
22. Ren B, Yee KO, Lawler J, Khosravi-Far R. Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta 2006;1765:178-88
23. Ruegg C, Hasmim M, Lejeune FJ, Alghisi GC. Antiangiogenic peptides and proteins: from experimental tools to clinical drugs. Biochim Biophys Acta 2006;1765:155-77
24. Ribatti D, Conconi MT, Nussdorfer GG. Nonclassic endogenous regulators of angiogenesis. Pharmacol Rev 2007;59:185-205
25. Guidolin D, Albertin G, Ribatti D. Urotensin-II as an angiogenic factor. Peptides 2010;31:1219-24
26. Ribatti D. Angiogenic activity of classical hematopoietic cytokines. Leuk Res 2012;36:537-43
27. Tammela T, Enholm B, Alitalo K, Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc Res 2005;65:550-63
28. Roy H, Bhardwaj S, Yla-Herttuala S. Biology of vascular endothelial growth factors. FEBS Lett 2006;580:2879-87
29. Yla-Herttuala S, Rissanen TT, Vajanto I, Hartikainen J. Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 2007;49:1015-26
30. Zhang G, Suggs LJ. Matrices and scaffolds for drug delivery in vascular tissue engineering. Adv Drug Deliv Rev 2007;59:360-73
31. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 2006;39:469-78
32. Tabibiazar R, Rockson SG. Angiogenesis and the ischaemic heart. Eur Heart J 2001;22:903-18
33. Unemori EN, Ferrara N, Bauer EA, Amento EP. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol 1992;153:557-62
34. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-845
35. Venkataraman G, Raman R, Sasisekharan V, Sasisekharan R. Molecular characteristics of fibroblast growth factor-fibroblast growth factor receptor-heparin-like glycosaminoglycan complex. Proc Natl Acad Sci USA 1999;96:3658-63
36. Cao R, Brakenhielm E, Pawliuk R, et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 2003;9:604-13
37. Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997;277:242-5
38. Hirschi KK, Rohovsky SA, Beck LH, et al. Endothelial cells modulate the proliferation of mural cell precursors via platelet-derived growth factor-BB and heterotypic cell contact. Circ Res 1999;84:298-305
39. Alvarez RH, Kantarjian HM, Cortes JE. Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc 2006;81:1241-57
40. Mitsos S, Katsanos K, Koletsis E, et al. Therapeutic angiogenesis for myocardial ischemia revisited: basic biological concepts and focus on latest clinical trials. Angiogenesis 2012;15:1-22
41. Itoh N, Ornitz DM. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem 2011;149:121-30
42. Buschmann IR, Hoefer IE, van Royen N, et al. GM-CSF: a strong arteriogenic factor acting by amplification of monocyte function. Atherosclerosis 2001;159:343-56
43. Yamada N, Li W, Ihaya A, et al. Platelet-derived endothelial cell growth factor gene therapy for limb ischemia. J Vasc Surg 2006;44:1322-8
44. Heil M, Eitenmuller I, Schmitz-Rixen T, Schaper W. Arteriogenesis versus angiogenesis: similarities and differences. J Cell Mol Med 2006;10:45-55
45. Grundmann S, Piek JJ, Pasterkamp G, Hoefer IE. Arteriogenesis: basic mechanisms and therapeutic stimulation. Eur J Clin Invest 2007;37:755-66
46. Ishizawa K, Kubo H, Yamada M, et al. Hepatocyte growth factor induces angiogenesis in injured lungs through mobilizing endothelial progenitor cells. BiochemBiophys Res Commun 2004;324:276-80
47. Korbling M, Reuben JM, Gao H, et al. Recombinant human granulocyte-colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: a novel blood cell component for therapeutic vasculogenesis. Transfusion 2006;46:1795-802
48. Schantz JT, Chim H, Whiteman M. Cell guidance in tissue engineering: SDF-1 mediates site-directed homing of mesenchymal stem cells within three-dimensional polycaprolactone scaffolds. Tissue Eng 2007;13:2615-24
49. Thevenot PT, Nair AM, Shen J, et al. The effect of incorporation of SDF-1alpha into PLGA scaffolds on stem cell recruitment and the inflammatory response. Biomaterials 2012;31:3997-4008
50. Pola R, Ling LE, Silver M, et al. The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat Med 2001;7:706-11
51. Yeh JL, Giordano FJ. Gene-based therapeutic angiogenesis. Semin Thorac Cardiovasc Surg 2003;15:236-49
52. Harats D, Kurihara H, Belloni P, et al. Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter. J Clin Invest 1995;95:1335-44
53. Kasahara N, Dozy AM, Kan YW. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 1994;266:1373-6
54. Leitner GC, Gruber R, Neumuller J, et al. Platelet content and growth factor release in platelet-rich plasma: a comparison of four different systems. Vox Sang 2006;91:135-9
55. Papanas N, Maltezos E. Benefit-risk assessment of becaplermin in the treatment of diabetic foot ulcers. Drug Saf 2010;33:455-61
56. Prokop A, Kozlov E, Nun Non S, et al. Towards retrievable vascularized bioartificial pancreas: induction and long-lasting stability of polymeric mesh implant vascularized with the help of acidic and basic fibroblast growth factors and hydrogel coating. Diabetes Technol Ther 2001;3:245-61
57. Demirdogen B, Elcin AE, Elcin YM. Neovascularization by bFGF releasing hyaluronic acid-gelatin microspheres: in vitro and in vivo studies. Growth Factors 2010;28:426-36
58. Borselli C, Ungaro F, Oliviero O, et al. Bioactivation of collagen matrices through sustained VEGF release from PLGA microspheres. J Biomed Mater Res A 2010;92:94-102
59. de Boer R, Knight AM, Spinner RJ, et al. In vitro and in vivo release of nerve growth factor from biodegradable polylactic-co-glycolic-acid microspheres. J Biomed Mater Res A 2012;95:1067-73
60. d'Angelo I, Garcia-Fuentes M, Parajo Y, et al. Nanoparticles based on PLGA: poloxamer blends for the delivery of proangiogenic growth factors. Mol Pharm 2010;7:1724-33
61. Karal-Yilmaz O, Serhatl M, Baysal K, Baysal BM. Preparation and in vitro characterization of vascular endothelial growth factor (VEGF)-loaded poly(d, llactic-co-glycolic acid) microspheres using a double emulsion/solvent evaporation technique. J Microencapsul 2011;28:46-54
62. Layman H, Xi XL, Nagar E, et al. Enhanced angiogenic efficacy through controlled and sustained delivery of FGF-2 and G-CSF from fibrin hydrogels containing ionic-albumin microspheres. J Biomater Sci Polym Ed 2012;23:185-206
63. Lee KY, Mooney DJ. Hydrogels for tissue engineering. Chem Rev 2001;101:1869-79
64. Steffens GC, Yao C, Prevel P, et al. Modulation of angiogenic potential of collagen matrices by covalent incorporation of heparin and loading with vascular endothelial growth factor. Tissue Eng 2004;10:1502-9
65. Young S, Wong M, Tabata Y, Mikos AG. Gelatin as a delivery vehicle for the controlled release of bioactive molecules. J Control Release 2005;109:256-74
66. Ishihara M, Obara K, Nakamura S, et al. Chitosan hydrogel as a drug delivery carrier to control angiogenesis. J Artif Organs 2006;9:8-16
67. Silva EA, Mooney DJ. Spatiotemporal control of vascular endothelial growth factor delivery from injectable hydrogels enhances angiogenesis. J Thromb Haemost 2007;5:590-8
68. Briganti E, Spiller D, Mirtelli C, et al. A composite fibrin-based scaffold for controlled delivery of bioactive pro-angiogenetic growth factors. J Control Release 2010;142:14-21
69. King TW, Patrick CW Jr. Development and in vitro characterization of vascular endothelial growth factor (VEGF)-loaded poly(D,L-lactic-co-glycolic acid)/poly (ethylene glycol) microspheres using a solid encapsulation/single emulsion/solvent extraction technique. J Biomed Mater Res 2000;51:383-90
70. Murphy WL, Peters MC, Kohn DH, Mooney DJ. Sustained release of vascular endothelial growth factor from mineralized poly(lactide-co-glycolide) scaffolds for tissue engineering. Biomaterials 2000;21:2521-7
71. Cleland JL, Duenas ET, Park A, et al. Development of poly-(D,Llactide- coglycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis. J Control Release 2001;72:13-24
72. Roy RS, Roy B, Sengupta S. Emerging technologies for enabling proangiogenic therapy. Nanotechnology 2011;22:494004
73. Richardson TP, Peters MC, Ennett AB, Mooney DJ. Polymeric system for dual growth factor delivery. Nat Biotechnol 2001;19:1029-34
74. Peirce SM, Price RJ, Skalak TC. Spatial and temporal control of angiogenesis and arterializations using focal applications of VEGF164 and Ang-1. Am J Physiol Heart Circ Physiol 2004;286:H918-25
75. Baiguera S, Ribatti D. Endothelialization approaches for viable engineered tissues. Angiogenesis 2013;16:1-14
76. Gupta R, Tongers J, Losordo DW. Human studies of angiogenic gene therapy. Circ Res 2009;105:724-36
77. Lekas M, Lekas P, Latter DA, et al. Growth factor-induced therapeutic neovascularization for ischaemic vascular disease: time for a re-evaluation? Curr Opin Cardiol 2006;21:376-84
78. Banai S, Jaklitsch MT, Shou M, et al. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 1994;89:2183-9
79. Harada K, Friedman M, Lopez JJ, et al. Vascular endothelial growth factor administration in chronic myocardial ischemia. Am J Physiol 1996;270:H1791-802
80. Sellke FW, Li J, Stamler A, et al. Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia. Surgery 1996;120:182-8
81. Henry TD, Annex BH, McKendall GR, et al. The VIVA trial: vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 2003;107:1359-65
82. Simons M, Annex BH, Laham RJ, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 2002;105:788-93
83. Henry TD, Rocha-Singh K, Isner JM, et al. Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. Am Heart J 2001;142:872-80
84. Hendel RC, Henry TD, Rocha-Singh K, et al. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. Circulation 2000;101:118-21
85. Jones DS, Silverman AP, Cochran JR. Developing therapeutic proteins by engineering ligand receptor interactions Trends Biotechnol. 2008;26:498-505
86. Sinha Roy R, Soni S, Harfouche R, et al. Coupling growth-factor engineering with nanotechnology for therapeutic angiogenesis. Proc Natl Acad. Sci. USA 2010;107:13608-13
87. Huang M, Vitharana SN, Peek LJ, et al. Polyelectrolyte complexes stabilize and controllably release vascular endothelial growth factor. Biomacromolecules 2007;8:1607-14
88. Chung YI, Kim SK, Lee YK, et al. Efficient revascularization by VEGF administration via heparin-functionalized nanoparticle-fibrin complex. J Control Release 2010;143:282-9
89. Jain RK, Au P, Tam AJ, et al. Engineering vascularized tissue. Nat Biotechnol 2005;23:821-82
90. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389-95
91. Hirschi KK, Skalak TC, Peirce SM, Little CD. Vascular assembly in natural and engineered tissues. Ann NY Acad Sci 2002;961:223-42
92. Asahara T, Bauters C, Zheng LP, et al. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 1995. 92: II365-71
93. Chen RR, Silva EA, Yuen WW, Mooney DJ. Spatio-temporal VEGF and PDGF delivery patterns blood vessel formation and maturation. Pharm Res 2007;24:258-64
94. Post J, Laham R, Sellke FW, Simons M. Therapeutic angiogenesis in cardiology using protein formulations. Cardiovasc Res 2001;49:522-31
95. Anitua E, Sanchez M, Orive G, Andia I. Delivering growth factors for therapeutics. Trends Pharmacol Sci 2008;29:37-41
96. Sun Q, Silva E A, Wang A, et al. Sustained release of multiple growth factors from injectable polymeric system as a novel therapeutic approach towards angiogenesis. Pharm Res 2010;27:264-71
97. Lee K, Silva EA, Mooney DJ. Growth factor delivery-based tissue engineering: general approaches and a review of recent developments. JR Soc Interface 2011;8:153-70
98. Shizukuda Y, Tang S, Yokota R, et al. Vascular endothelial growth factor-induced endothelial cell migration and proliferation depend on a nitric oxide-mediated decrease in protein kinase C delta activity. Circ Res 1999;85:247-56
99. Babaei S, Teichert-Kuliszewska K, Zhang Q, et al. Angiogenic actions of angiopoietin-1 require endothelium-derived nitric oxide. Am J Pathol 2003;162:1927-36
100. Ziche M, Morbidelli L. Nitric oxide and angiogenesis. J Neurooncol 2000;50:139-48
101. Lee PC, Salyapongse AN, Bragdon GA, et al. Impaired wound healing and angiogenesis in eNOS-deficient mice. Am J Physiol 1999;277:H1600-8
102. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999;85:221-8
103. Takahashi T, Kalka C, Masuda H, et al. Ischemia and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999;4:434-8
104. Lazarous DF, Shou M, Stiber JA, et al. Adenoviral-mediated gene transfer induces sustained pericardial VEGF expression in dogs: effect on myocardial angiogenesis. Cardiovasc Res 1999;44:294-302
105. Garcia-Martinez C, Opolon P, Trochon V, et al. Angiogenesis induced in muscle by a recombinant adenovirus vector expressing functional isoforms of basic fibroblast growth factor. Gene Ther 1999;6:1210-21
106. Ueda H, Sawa Y, Matsumoto K, et al. Gene transfection of hepatocyte growth factor attenuates reperfusion injury in the heart. Ann Thor Surg 1999;67:1726-31
107. Green JJ, Langer R, Anderson DG. A combinatorial polymer library approach yields insight into nonviral gene delivery. Acc Chem Res 2008;41:749-59
108. Lederman RJ, Mendelsohn FO, Anderson RD, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomized trial. Lancet 2002;359:2053-8
109. Rajagpalan S, Mohler ER III, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003;108:1933
110. Losordo DW, Vale PR, Hendel RC, et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002;105:2012-18
111. Henry TD, Annex BH, McKendall GR, et al. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 2003;107:1359-65
112. Simons M, Annex BH, Laham RJ, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2. Double-blind, randomized, controlled clinical trial. Circulation 2002;105:788-93
113. Grines CL, Watkins MW, Helmer G, et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002;105:1291-7
114. Doukas J, Blease K, Craig D, et al. Delivery of FGF genes to wound repair cells enhances arteriogenesis and myogenesis in skeletal muscle. Mol Ther 2002;5:517-27
115. Stewart DJ, Hilton JD, Arnold MO, et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized controlled trial of AdVEGF121 versus maximum medical treatment. Gene Ther 2006;13:1503-11
116. Kastrup J, Jorgensen E, Ruck A, et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris. A randomized double-blind placebo-controlled study: the Euroinject-One trial. J Am Coll Cardiol 2005;45:982-8
117. Gyongyosi M, Khorsand A, Zamini S, et al. NOGA-guided analysis of regional myocardial perfusion abnormalities treated with intramyocardial injections of plasmid encoding vascular endothelial growth factor A-165 in patients with chronic myocardial ischemia: subanalysis of the EUROINJECT-ONE multicenter double-blind randomized study. Circulation 2005;112(9 Suppl):157-65
118. Kastrup J, Jorgensen E, Fuchs S, et al. A randomized, double-blind, placebo-controlled, multicentre study of the safety and efficacy of BIOPYPASS (AdGVVEGF121.10NH) gene therapy in patients with refractory advanced coronary artery disease: the NOVA trial. EuroIntervention 2011;6:813-18
119. Lekas M, Lehas P, Latter DA, et al. Growth factor-induced therapeutic neovascularization for ischemic vascular disease: time for re-evaluation ? Curr Opin Cardiol 2006;21:376-84
120. Cho SW, Moon SH, Lee SH, et al. Improvement of postnatal neovascularization by human embryonic stem cell derived endothelial-like cell transplantation in a mouse model of hind limb ischemia. Circulation 2007;116:2409-19
121. Kamihata H, Matsubara H, Nishiue T, et al. implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation 2001;104:1046-52
122. Lara-Hernandez R, Lozano-Vilardell P, Blanes P, et al. Safety and efficacy of therapeutic angiogenesis as a novel treatment in patients with critical limb ischemia. Ann Vasc Surg 2010;24:287-94